LGH-447

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H23F3N4O
Molecular Weight	440.4608
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H]1C[C@H](N)C[C@@H](C1)C2=C(NC(=O)C3=NC(=C(F)C=C3)C4=C(F)C=CC=C4F)C=NC=C2

InChI

InChIKey=VRQXRVAKPDCRCI-ZNMIVQPWSA-N

InChI=1S/C24H23F3N4O/c1-13-9-14(11-15(28)10-13)16-7-8-29-12-21(16)31-24(32)20-6-5-19(27)23(30-20)22-17(25)3-2-4-18(22)26/h2-8,12-15H,9-11,28H2,1H3,(H,31,32)/t13-,14+,15-/m0/s1

HIDE SMILES / InChI

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serine/threonine-protein kinase PIM 1 Target ID: CHEMBL3559682 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27471867 \| https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C106259	Inhibitor 8504

C_max

Value	Dose	Analyte	Population
1610 ng/mL EXPERIMENT https://link.springer.com/article/10.1007/s12185-021-03096-9	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	LGH-447 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4260 ng/mL EXPERIMENT https://link.springer.com/article/10.1007/s12185-021-03096-9	250 mg 1 times / day steady-state, oral dose: 250 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LGH-447 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1800 ng/mL EXPERIMENT https://link.springer.com/article/10.1007/s12185-021-03096-9	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	LGH-447 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7600 ng/mL EXPERIMENT https://link.springer.com/article/10.1007/s12185-021-03096-9	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LGH-447 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1480 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31092894/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	LGH-447 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4220 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31092894/	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LGH-447 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
22800 ng × h/mL EXPERIMENT https://link.springer.com/article/10.1007/s12185-021-03096-9	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	LGH-447 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
105000 ng × h/mL EXPERIMENT https://link.springer.com/article/10.1007/s12185-021-03096-9	250 mg 1 times / day steady-state, oral dose: 250 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LGH-447 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
26100 ng × h/mL EXPERIMENT https://link.springer.com/article/10.1007/s12185-021-03096-9	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	LGH-447 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
88500 ng × h/mL EXPERIMENT https://link.springer.com/article/10.1007/s12185-021-03096-9	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LGH-447 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
22100 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31092894/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	LGH-447 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
83400 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31092894/	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LGH-447 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
51 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31092894/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		LGH-447 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
43 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31092894/	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		LGH-447 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
5% EXPERIMENT https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01275	single, unknown		LGH-447 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Name

Type

Language

LGH447

Preferred Name

English

LGH-447

Code

English

N-(4-((1R,3S,5S)-3-AMINO-5-METHYLCYCLOHEXYL)-3-PYRIDINYL)-6-(2,6-DIFLUOROPHENYL)-5-FLUORO-2-PYRIDINECARBOXAMIDE

Systematic Name

English

PIM-447

Code

English

PIM KINASE INHIBITOR LGH447

Common Name

English

PIM447

Code

English

PIM 447 [WHO-DD]

Common Name

English

2-PYRIDINECARBOXAMIDE, N-(4-((1R,3S,5S)-3-AMINO-5-METHYLCYCLOHEXYL)-3-PYRIDINYL)-6-(2,6-DIFLUOROPHENYL)-5-FLUORO-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1404